Encrypted login | home

Program Information

The Imaging and Radiation Oncology Core Houston (IROC Houston) QA Center International Activities Outside North America

D Followill

D Followill*, S Kry , A Molineu , J Lowenstein , P Alvarez , P Taylor , H Nguyen , N Hernandez , C Lujano , T Nguyen , T Keith , J Roll , A Tailor , UT MD Anderson Cancer Center, Houston, TX


TU-G-BRD-6 (Tuesday, July 14, 2015) 4:30 PM - 6:00 PM Room: Ballroom D

Purpose:To describe the extent of IROC Houston’s (formerly the RPC) QA activities and audit results for radiotherapy institutions outside of North America (NA).

Methods:The IROC Houston’s QA program components were designed to audit the radiation dose calculation chain from the NIST traceable reference beam calibration, to inclusion of dosimetry parameters used to calculate tumor doses, to the delivery of the radiation dose. The QA program provided to international institutions includes: 1) remote TLD/OSLD audit of machine output, 2) credentialing for advanced technologies, and 3) review of patient treatment records. IROC Houston uses the same standards and acceptance criteria for all of its audits whether for North American or international sites.

Results:IROC Houston’s QA program has reached out to radiotherapy sites in 43 different countries since 2013 through their participation in clinical trials. In the past two years, 2,778 international megavoltage beam outputs were audited with OSLD/TLD. While the average IROC/Inst ratio is near unity for all sites monitored, there are international regions whose results are significantly different from the NA region. In the past 2 years, 477 and 87 IMRT H&N phantoms were irradiated at NA and international sites, respectively. Regardless of the OSLD beam audit results, the overall pass rate (87 percent) for all international sites (no region separation) is equal to the NA sites. Of the 182 international patient charts reviewed, 10.7 percent of the dose calculation points did not meet our acceptance criterion as compared to 13.6 percent for NA sites. The lower pass rate for NA sites results from a much larger brachytherapy component which has been shown to be more error prone.

Conclusion:IROC Houston has expanded its QA services worldwide and continues a long history of improving radiotherapy dose delivery in many countries.

Funding Support, Disclosures, and Conflict of Interest: Funding received for QA audit services from the Korean GOG, DAHANCA, EORTC, ICON and CMIC Group

Contact Email: